DiaMedica Therapeutics Inc. (DMAC) stock forecast and price target
Price $8.79 · data as of November 13, 2026
12-month price target
Average target$15.50
Upside / downside+76.3%
Analysts4
ConsensusStrong buy
Low $11.00Average $15.50High $25.00
Gold marker: average target · white marker: today’s price ($8.79)
Analyst ratings
Strong buy 0Buy 5Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.79 | −12.9% | $0 |
| Next fiscal year ends December 31, 2027 | $-0.75 | +5.1% | $0 |
| Next quarter ends December 31, 2026 | $-0.21 | −23.5% | $0 |
| Quarter after ends March 31, 2027 | $-0.19 | +0.0% | $0 |
Consensus of the analysts covering DiaMedica Therapeutics, updated daily. In the last 30 days 3 estimates were raised and 0 lowered.
Frequently asked questions
What is the DiaMedica Therapeutics stock price target?
The average 12-month target from 4 analysts is $15.50, 76.3% above the current price of $8.79 Targets range from $11.00 to $25.00.
Is DiaMedica Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (5 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is DiaMedica Therapeutics expected to earn?
Analysts expect EPS of $-0.79 for the fiscal year ending December 31, 2026 and $-0.75 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.